Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): A single centre experience

Haemophilia

Volumn 20, Issue 6, 2014, Pages 846-853

  Batty, P ^a   Chen, Y H ^a   Bowles, L ^a   Hart, D P ^a   Platton, S ^a   Pasi, K John ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Bleeding; Efficacy; Plasma concentrate; Prophylaxis; Surgery; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; DRUG COMBINATION; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BACKACHE; BLEEDING; CHEMOPROPHYLAXIS; CHEST TIGHTNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FLUSHING; HEMOPHILIA; HOME CARE; HUMAN; INFECTION; INFUSION RELATED REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VON WILLEBRAND DISEASE; ADVERSE EFFECTS; COMPLICATION; DRUG COMBINATION; HEMORRHAGE; INJURY; MIDDLE AGED; PREMEDICATION; SURGERY; TREATMENT OUTCOME; VERY ELDERLY; VON WILLEBRAND DISEASES; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DRUG COMBINATIONS; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84932088154     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12496     Document Type: Article

References (22)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
2. United Kingdom Haemophilia Centres Doctors' Organisation. Bleeding disorder statistics for April 2011 to March 2012: a report from the national haemophilia database. 1-87. 2012.
3. Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-31.
4. Mannucci PM, Kempton C, Millar C et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122: 648-57.
5. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
6. Stadler M, Gruber G, Kannicht C et al. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006; 34: 281-8.
7. Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS. The pharmacokinetic diversity of two von Willebrand factor (VWF)/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. Thromb Haemost 2011; 106: 279-88.
8. Windyga J, von Depka-Prondzinski M. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate(R)) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011; 105: 1072-9.
9. Laffan M, Brown SA, Collins PW et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217.
10. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
11. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
12. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-5.
13. Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease-efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia 2009; 15: 122-30.
14. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16(Suppl 1): S17-21.
15. Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies. Haemophilia 2012; 18: e164-72.
16. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002; 88: 387-8.
17. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
18. Coppola A, Franchini M, Makris M, Santagostino E, Di MG, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173-87.
19. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-94.
20. Raquet E, Stockschlader M, Dickneite G. Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. Haemophilia 2011; 17: 808-14.
21. Kessler CM, Windyga J, Schwartz BA, Knaub S. Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates. Blood Coagul Fibrinolysis 2012; 23: 262-7.
22. Berntorp E, Fuchs B, Makris M et al. Third Aland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia 2013; 19(Suppl 3): 1-18.